1-1 of 1
Keywords: Pembrolizumab
Sort by
Journal Articles
Gynecol Obstet Invest (2019) 84 (1): 94–98.
Published Online: 17 July 2018
... of systemic chemotherapy is poor. No biologic or targeted agents have been approved for the management of advanced or recurrent vulvar cancer. Pembrolizumab, a humanized monoclonal antibody against programmed death 1 (PD-1), has been successfully used as a target of tumor immune therapy in small cell lung...